G Schifitto

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. pmc Selegiline and oxidative stress in HIV-associated cognitive impairment
    G Schifitto
    University of Rochester, NY, USA
    Neurology 73:1975-81. 2009
  2. pmc Lithium therapy for human immunodeficiency virus type 1-associated neurocognitive impairment
    Giovanni Schifitto
    Department of Neurology, University of Rochester, Rochester, New York, USA
    J Neurovirol 15:176-86. 2009
  3. pmc Fatigue in levodopa-naive subjects with Parkinson disease
    G Schifitto
    University of Rochester, NY, USA
    Neurology 71:481-5. 2008
  4. ncbi request reprint Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study
    Giovanni Schifitto
    University of Rochester, Rochester, New York 14620, USA
    AIDS 21:1877-86. 2007
  5. ncbi request reprint Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report
    G Schifitto
    Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
    Neurology 66:919-21. 2006
  6. ncbi request reprint A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment
    G Schifitto
    Department of Neurology, Movement and Inherited Neurologic Disorders, Clinical Trials Coordination Center, 1351 Mount Hope Avenue, Suite 223, Rochester, NY 14620, USA
    Neurology 69:1314-21. 2007
  7. ncbi request reprint Markers of immune activation and viral load in HIV-associated sensory neuropathy
    G Schifitto
    Department of Neurology, University of Rochester, 601 Elmwood Ave, Box 673, Rochester, NY 14642, USA
    Neurology 64:842-8. 2005
  8. ncbi request reprint A placebo-controlled study of memantine for the treatment of human immunodeficiency virus-associated sensory neuropathy
    Giovanni Schifitto
    University of Rochester, Rochester, New York 14620, USA
    J Neurovirol 12:328-31. 2006
  9. ncbi request reprint Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia
    J J Sevigny
    Columbia University and The Taub Institute, New York, NY 10032, USA
    Neurology 63:2084-90. 2004
  10. ncbi request reprint A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment
    D B Clifford
    Department of Neurology, Washington University, St Louis, MO 63110, USA
    Neurology 59:1568-73. 2002

Research Grants

  1. Selegiline, Oxidative Stress and MRS in HIV Dementia
    Giovanni Schifitto; Fiscal Year: 2001
  2. Selegiline, Oxidative Stress and MRS in HIV Dementia
    Giovanni Schifitto; Fiscal Year: 2002
  3. Selegiline, Oxidative Stress and MRS in HIV Dementia
    Giovanni Schifitto; Fiscal Year: 2003

Detail Information

Publications44

  1. pmc Selegiline and oxidative stress in HIV-associated cognitive impairment
    G Schifitto
    University of Rochester, NY, USA
    Neurology 73:1975-81. 2009
    ....
  2. pmc Lithium therapy for human immunodeficiency virus type 1-associated neurocognitive impairment
    Giovanni Schifitto
    Department of Neurology, University of Rochester, Rochester, New York, USA
    J Neurovirol 15:176-86. 2009
    ....
  3. pmc Fatigue in levodopa-naive subjects with Parkinson disease
    G Schifitto
    University of Rochester, NY, USA
    Neurology 71:481-5. 2008
    ..Fatigue is a common complaint in Parkinson disease (PD). We investigated fatigue in a cohort of previously untreated patients with early PD enrolled in the Earlier vs Later Levodopa (ELLDOPA) clinical trial...
  4. ncbi request reprint Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study
    Giovanni Schifitto
    University of Rochester, Rochester, New York 14620, USA
    AIDS 21:1877-86. 2007
    ..To assess the safety and efficacy of memantine, an uncompetitive antagonist of the N-methyl-D-aspartate receptor as treatment of HIV-associated cognitive impairment...
  5. ncbi request reprint Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report
    G Schifitto
    Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
    Neurology 66:919-21. 2006
    ..VPA was safe and well tolerated, with trends toward improved neuropsychological performance and brain metabolism in the impaired subjects...
  6. ncbi request reprint A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment
    G Schifitto
    Department of Neurology, Movement and Inherited Neurologic Disorders, Clinical Trials Coordination Center, 1351 Mount Hope Avenue, Suite 223, Rochester, NY 14620, USA
    Neurology 69:1314-21. 2007
    ..This rationale has led to the design and implementation of this Selegiline Transdermal System (STS) study with the primary aims of assessing safety and tolerability of STS as well as improvement in cognitive performance...
  7. ncbi request reprint Markers of immune activation and viral load in HIV-associated sensory neuropathy
    G Schifitto
    Department of Neurology, University of Rochester, 601 Elmwood Ave, Box 673, Rochester, NY 14642, USA
    Neurology 64:842-8. 2005
    ..The pathogenesis of DSP is unknown, although both HIV proteins and products of immune activation triggered by HIV infection have been implicated...
  8. ncbi request reprint A placebo-controlled study of memantine for the treatment of human immunodeficiency virus-associated sensory neuropathy
    Giovanni Schifitto
    University of Rochester, Rochester, New York 14620, USA
    J Neurovirol 12:328-31. 2006
    ..Results were similar to those of other pilot studies of memantine for neuropathic pain unrelated to HIV, suggesting that memantine is ineffective for the symptomatic treatment of HIV-associated SDSP...
  9. ncbi request reprint Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia
    J J Sevigny
    Columbia University and The Taub Institute, New York, NY 10032, USA
    Neurology 63:2084-90. 2004
    ....
  10. ncbi request reprint A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment
    D B Clifford
    Department of Neurology, Washington University, St Louis, MO 63110, USA
    Neurology 59:1568-73. 2002
    ..It has neuroprotective properties in model systems for HIV-associated neurotoxicity and thus is a candidate for neuroprotective therapy in humans with HIV-associated CNS disease...
  11. ncbi request reprint A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291
    J C McArthur
    Department of Neurology, Johns Hopkins University, Baltimore, MD, USA
    Neurology 54:1080-8. 2000
    ..To evaluate the safety and efficacy of recombinant human nerve growth factor (rhNGF) in HIV-associated sensory neuropathy (SN) within a multicenter, placebo-controlled, randomized trial (ACTG 291)...
  12. ncbi request reprint Factors associated with incident human immunodeficiency virus-dementia
    Y Stern
    Department of Neurology and Gertrude H Sergievsky Center, Columbia University College of Physicians and Surgeons, 630 W 168th St, New York, NY 10032, USA
    Arch Neurol 58:473-9. 2001
    ..Antecedents to human immunodeficiency virus-dementia (HIV-D) are poorly understood...
  13. ncbi request reprint Inter-rater reliability of a clinical staging of HIV-associated cognitive impairment
    K Marder
    Department of Neurology, Sergievsky Center, New York, NY 10032, USA
    Neurology 60:1467-73. 2003
    ..To determine the inter-rater reliability of a modification of the Memorial Sloan-Kettering (MSK) Staging for HIV-associated cognitive impairment...
  14. ncbi request reprint Clinical trials in HIV-associated cognitive impairment: cognitive and functional outcomes
    G Schifitto
    Department of Neurology, University of Rochester, NY, USA
    Neurology 56:415-8. 2001
    ..Modifications of current functional scales or new functional instruments are needed to assess the clinical relevance of cognitive changes in clinical trials of HIV-associated cognitive impairment...
  15. ncbi request reprint Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study
    N Sacktor
    Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
    Neurology 54:233-5. 2000
    ..Both selegiline and placebo were well tolerated with few adverse events. Improvements favoring the selegiline group were suggested on single tests of verbal memory and motor/psychomotor performance, warranting a larger study...
  16. ncbi request reprint Autonomic performance and dehydroepiandrosterone sulfate levels in HIV-1-infected individuals: relationship to TH1 and TH2 cytokine profile
    G Schifitto
    Department of Neurology, University of Rochester, 601 Elmwood Ave, Box 673, Rochester, NY 14642
    Arch Neurol 57:1027-32. 2000
    ..In animal models, autonomic and endocrine dysfunction are associated with an altered cytokine profile...
  17. ncbi request reprint Is skin biopsy a predictor of transition to symptomatic HIV neuropathy? A longitudinal study
    D N Herrmann
    Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
    Neurology 66:857-61. 2006
    ....
  18. ncbi request reprint Incidence of and risk factors for HIV-associated distal sensory polyneuropathy
    G Schifitto
    Department of Neurology, University of Rochester, Rochester, NY 14642, USA
    Neurology 58:1764-8. 2002
    ..To assess the incidence of and risk factors for distal sensory polyneuropathy (DSP) in a cohort of HIV-infected subjects...
  19. ncbi request reprint Long-term treatment with recombinant nerve growth factor for HIV-associated sensory neuropathy
    G Schifitto
    Department of Neurology, University of Rochester, NY 14642, USA
    Neurology 57:1313-6. 2001
    ..However, there was no improvement of neuropathy severity as assessed by neurologic examination, quantitative sensory testing, and epidermal nerve fiber density...
  20. pmc Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial
    D M Simpson
    Mount Sinai School of Medicine, New York, NY, USA
    Neurology 74:413-20. 2010
    ..Pregabalin is effective in several neuropathic pain syndromes. This trial evaluated its efficacy, safety, and tolerability for treatment of painful HIV-associated neuropathy...
  21. pmc Minocycline treatment for HIV-associated cognitive impairment: results from a randomized trial
    N Sacktor
    Department of Neurology, Johns Hopkins Bayview Medical Center, 4940 Eastern Ave, 301 Building, Suite 2100, Baltimore, MD 21224, USA
    Neurology 77:1135-42. 2011
    ..We conducted a study of minocycline to assess its safety, tolerability, and efficacy for the treatment of HIV-associated cognitive impairment...
  22. ncbi request reprint Reduced intraepidermal nerve fiber density in HIV-associated sensory neuropathy
    M Polydefkis
    Department of Neurology, Johns Hopkins University, Baltimore, MD, USA
    Neurology 58:115-9. 2002
    ..To explore the relationship between intraepidermal nerve fiber (IENF) density in HIV-associated sensory neuropathy (HIV-SN) to measurements of neuropathy severity and progression of HIV disease...
  23. doi request reprint Lopinavir cerebrospinal fluid steady-state trough concentrations in HIV-infected adults
    Robert Dicenzo
    Wegmans School of Pharmacy, St John Fisher College, Rochester, NY 14618, USA
    Ann Pharmacother 43:1972-7. 2009
    ..The central nervous system may act as a sanctuary site for viral replication in the setting of low antiretroviral penetration. Data on lopinavir cerebrospinal fluid (CSF) trough concentration (C(trough)) values have yet to be reported...
  24. pmc Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance
    Christina M Marra
    Department of Neurology, University of Washington School of Medicine, Seattle, USA
    AIDS 23:1359-66. 2009
    ..To determine whether antiretroviral regimens with good central nervous system (CNS) penetration control HIV in cerebrospinal fluid (CSF) and improve cognition...
  25. ncbi request reprint Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels
    David M Simpson
    Department of Neurology, Mount Sinai School of Medicine, 1 Gustave L Levy Place, Box 1052, New York, NY 10029, USA
    AIDS 16:407-12. 2002
    ..To determine if there is an association between plasma HIV-1 RNA levels and severity of HIV-associated distal symmetrical polyneuropathy (DSP)...
  26. ncbi request reprint Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
    E R Dorsey
    Department of Neurology, University of Rochester Medical Center, 1351 Mt Hope Blvd, Suite 223, Rochester, NY 14620, USA
    Neurology 68:384-6. 2007
    ..The number of individuals with PD over age 50 in these countries was between 4.1 and 4.6 million in 2005 and will double to between 8.7 and 9.3 million by 2030...
  27. pmc Clinical, laboratory, and neuroimaging characteristics of fatigue in HIV-infected individuals
    Giovanni Schifitto
    University of Rochester, Rochester, NY, USA
    J Neurovirol 17:17-25. 2011
    ..This observation, taken together with the association between fatigue and neuropsychological tests of frontal lobe performance is consistent with the hypothesis of a striatal-cortical circuitry involvement in the symptoms of fatigue...
  28. pmc Effects of minocycline and valproic acid coadministration on atazanavir plasma concentrations in human immunodeficiency virus-infected adults receiving atazanavir-ritonavir
    Robert Dicenzo
    University at Buffalo, Buffalo, New York, USA
    Antimicrob Agents Chemother 52:3035-9. 2008
    ..2). Minocycline coadministration resulted in decreased atazanavir exposure, and there was no evidence that the addition of valproic acid mediated this effect...
  29. ncbi request reprint Epidermal nerve fiber density, axonal swellings and QST as predictors of HIV distal sensory neuropathy
    David N Herrmann
    Department of Neurology, University of Rochester, SMH 601 Elmwood Avenue, Box 673, Rochester, New York 14642, USA
    Muscle Nerve 29:420-7. 2004
    ..03, 95% CI 1.01-1.05) were the only two measures associated with a shorter time to development of symptomatic DSP. Quantitation of ENF swellings and heat pain thresholds deserve further study as predictors of symptomatic neuropathy...
  30. pmc Effects of valproic acid coadministration on plasma efavirenz and lopinavir concentrations in human immunodeficiency virus-infected adults
    Robert Dicenzo
    University of Rochester Medical Center, Clinical Pharmacology Unit, 601 Elmwood Ave, Box 315, Room 1 6124, Rochester, NY 14642, USA
    Antimicrob Agents Chemother 48:4328-31. 2004
    ..LPV concentrations tended to be higher when the drug was combined with VPA. Results of VPA comparisons fail to raise concern that coadministration with EFV or LPV/r will significantly influence trough concentrations of VPA...
  31. ncbi request reprint Oxidative stress in HIV demented patients and protection ex vivo with novel antioxidants
    J Turchan
    Department of Neurology, Pharmaceutical Sciences, University of Kentucky, Lexington, USA
    Neurology 60:307-14. 2003
    ..To determine the role of oxidative stress in mediating HIV dementia and to identify novel therapeutic compounds that may block this oxidative stress...
  32. ncbi request reprint HIV-associated cognitive impairment before and after the advent of combination therapy
    Ned Sacktor
    Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21224, USA
    J Neurovirol 8:136-42. 2002
    ..Even though HAART has reduced the incidence of HIV dementia, HIV-associated cognitive impairment continues to be a major clinical problem among individuals with advanced infection...
  33. ncbi request reprint Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy
    Justin C McArthur
    Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD 21287 7609, USA
    Arch Neurol 61:1687-96. 2004
    ..Before the introduction of combination antiretroviral therapy (CART), neurological disease correlated with cerebrospinal fluid (CSF) levels of human immunodeficiency virus (HIV) RNA...
  34. ncbi request reprint Glycogen synthase kinase 3 beta (GSK-3 beta) as a therapeutic target in neuroAIDS
    Stephen Dewhurst
    Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY 14642, USA
    J Neuroimmune Pharmacol 2:93-6. 2007
    ..These findings highlight the therapeutic potential of GSK-3beta blockade...
  35. ncbi request reprint Inhibition of mixed lineage kinase 3 prevents HIV-1 Tat-mediated neurotoxicity and monocyte activation
    Ziye Sui
    Interdepartmental Program in Neuroscience, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, USA
    J Immunol 177:702-11. 2006
    ..In aggregate, our data define MLK3 as a promising therapeutic target for intervention in HAD...
  36. ncbi request reprint An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection
    Jeffrey J Sevigny
    Department of Neurology and Gertrude H Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, NY, USA
    Arch Neurol 64:97-102. 2007
    ..Several markers of immune activation have been identified as potential prognostic markers for human immunodeficiency virus (HIV)-associated morbidity and mortality, but the results from studies are conflicting...
  37. ncbi request reprint A multicenter study of two magnetic resonance spectroscopy techniques in individuals with HIV dementia
    Ned Sacktor
    Department of Neurology, Johns Hopkins Bayview Medical Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21224, USA
    J Magn Reson Imaging 21:325-33. 2005
    ..To evaluate single-voxel proton magnetic resonance spectroscopy (SV-MRS) and magnetic resonance spectroscopic imaging (MRSI) metabolite results in individuals with HIV dementia...
  38. ncbi request reprint Functional synergy between CD40 ligand and HIV-1 Tat contributes to inflammation: implications in HIV type 1 dementia
    Ziye Sui
    Interdepartmental Program in Neuroscience, University of Rochester School of Medicine, 601 Elmwood Avenue, Rochester, NY 14642, USA
    J Immunol 178:3226-36. 2007
    ..Taken together, our results show that CD40 signaling in microglia and monocytes can synergize with the effects of Tat, further amplifying inflammatory processes within the CNS and influencing neuronal survival...
  39. ncbi request reprint A multi-center 1H MRS study of the AIDS dementia complex: validation and preliminary analysis
    Patricia Lani Lee
    NMR Center, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02111, USA
    J Magn Reson Imaging 17:625-33. 2003
    ....
  40. ncbi request reprint Platelet decline: an avenue for investigation into the pathogenesis of human immunodeficiency virus -associated dementia
    Lynn M Wachtman
    Department of Molecular and Comparative Pathobiology, The Johns Hopkins University, Baltimore, Maryland 21287 7609, USA
    Arch Neurol 64:1264-72. 2007
    ..The identification of biomarkers identifying onset of human immunodeficiency virus-associated dementia (HIV-D) is critical for diagnosis and the elucidation of pathophysiologic pathways...
  41. ncbi request reprint Proton MRS and neuropsychological correlates in AIDS dementia complex: evidence of subcortical specificity
    Robert H Paul
    Department of Behavioral Neuroscience, University of Missouri, St Louis, St Louis, MO 63121, USA
    J Neuropsychiatry Clin Neurosci 19:283-92. 2007
    ..Prospective studies are needed to elucidate the evolution of these changes in the setting of antiretroviral therapy...
  42. ncbi request reprint Selegiline transdermal system (STS) for HIV-associated cognitive impairment: open-label report of ACTG 5090
    Scott R Evans
    Harvard School of Public Health, Boston, Massachusetts, USA
    HIV Clin Trials 8:437-46. 2007
    ..To assess the long-term safety (primary aim) and efficacy (secondary aim) of the MAO-B inhibitor Selegiline Transdermal System (STS) for the treatment of HIV-associated cognitive impairment...
  43. ncbi request reprint Regional patterns of brain metabolites in AIDS dementia complex
    Constantin T Yiannoutsos
    Division of Biostatistics, Indiana University School of Medicine, 1050 Wishard Boulevard, RG 4101, Indianapolis, IN 46202, USA
    Neuroimage 23:928-35. 2004
    ..We conclude that by using factor analysis, we are able to combine multiple metabolites across brain regions in a biologically plausible manner and construct a predictive model of ADC adjusting for relevant factors such as age...
  44. ncbi request reprint Chronic stress in nonelderly caregivers: psychological, endocrine and immune implications
    Kavita Vedhara
    MRC Health Services Research Collaboration, Department of Social Medicine, University of Bristol, Canynge Hall, UK
    J Psychosom Res 53:1153-61. 2002
    ..g., spousal caregivers of dementia patients) extends to a younger caregiver population, specifically spousal carers of patients with multiple sclerosis (MS)...

Research Grants3

  1. Selegiline, Oxidative Stress and MRS in HIV Dementia
    Giovanni Schifitto; Fiscal Year: 2001
    ..The proposed study will take advantage of the ACTG supporting A5090 study and of the existing MRS consortium infrastructure that will allow us to perform multicenter MRS studies. ..
  2. Selegiline, Oxidative Stress and MRS in HIV Dementia
    Giovanni Schifitto; Fiscal Year: 2002
    ..The proposed study will take advantage of the ACTG supporting A5090 study and of the existing MRS consortium infrastructure that will allow us to perform multicenter MRS studies. ..
  3. Selegiline, Oxidative Stress and MRS in HIV Dementia
    Giovanni Schifitto; Fiscal Year: 2003
    ..The proposed study will take advantage of the ACTG supporting A5090 study and of the existing MRS consortium infrastructure that will allow us to perform multicenter MRS studies. ..